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1 Drug description 
Generic/Brand name/ATC code:  
Nivolumab/Nivolumab BMS (for non-small cell lung cancer),  
Opdivo® (for melanoma)/L01XC17 
 
Developer/Company:  
Nivolumab was developed as a collaboration between Ono Pharmaceutical 
and Medarex. Medarex was acquired by Bristol-Meyers Squibb (BMS) in 2009. 
Ono Pharmaceutical and BMS have a strategic collaboration agreement to 
jointly develop and commercialise all collaboration products [1]. 
 
Description:  
The programmed cell death receptor-1 (PD-1) is expressed on a number of 
cell types, including activated T-cells, activated B-cells and natural killer cells. 
The PD-1 receptor is a negative regulator of T-cell activity that has been 
shown to be involved in the control of T-cell immune responses. Its main en-
dogenous ligands PD-L1 and PD-L2 are expressed in activated immune cells 
and in many tumour cells in response to inflammatory stimuli. Tumours have 
been shown to escape immune surveillance by expressing PD-L1 and PD-
L2, thereby suppressing tumour-infiltrating lymphocytes via PD-1/PD-L1, 2 
interactions and preventing immune-mediated rejection of the tumour. Nivo-
lumab is a fully human IgG4 monoclonal antibody that blocks binding of 
PD-1 to PD-L1. Inhibition of these interactions has been demonstrated to 
enhance T-cell response and cell-mediated immune response against tumour 
cells [2-4].  
Nivolumab is administered as an intravenous infusion over 60 minutes at a 
dose of 3 mg per kilogram of body weight every two weeks [4, 5]. 
 
 
 
2 Indication 
Nivolumab is indicated for the second-line therapy of metastatic squamous 
non-small cell lung cancer (NSCLC).  
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3 Current regulatory status 
In Europe, nivolumab received marketing authorisation: 
 for the treatment of locally advanced or metastatic squamous NSCLC 
after prior chemotherapy in adults under the brand name Nivolumab 
BMS® on 20 July 2015 [6]. 
 as monotherapy for the treatment of advanced (unresectable or meta-
static) melanoma in adults under the brand name Opdivo® on the 19 
June 2015 [4]. 
In the U.S., nivolumab is licensed for: 
 metastatic squamous NSCLC with progression on or after platinum-
based chemotherapy since March 2015.  
 unresectable or metastatic melanoma and disease progression follow-
ing ipilimumab and, if BRAF V600 mutation positive, as a BRAF in-
hibitor. This indication was approved under accelerated approval in 
December 2014 [5]. 
 
 
 
4 Burden of disease 
Primary lung cancer is the leading cause of cancer death worldwide. While the 
mortality of lung cancer is declining in men, increasing rates in women have 
been observed in Europe [7]. In Austria, 4,371 patients were newly diagnosed 
with lung cancer in 2011 equalling an incidence rate of 65.4 cases per 100,000 
persons. 3,619 patients died from lung cancer in 2011 [8]. In Germany, 52,717 
patients were newly diagnosed with lung cancer in 2011 resulting in an inci-
dence rate of 65.4 cases per 100,000 persons. 43,944 died in 2011 [9]. Age-
standardised rates show that incidence and mortality are about twice as high 
in men than in women, however, incidence is slowly decreasing in men but 
increasing in women.  
The most common type of lung cancer is NSCLC which accounts for about 
85%–90% of all lung cancers. Two major types of NSCLC can be distinguished: 
non-squamous and squamous cell (epidermoid) carcinoma. Of all NSCLC, 
histologically about 22% are squamous cell carcinomas [10] which are char-
acterised as presence of keratin production by tumour cells and/or intercel-
lular desmosomes (“intercellular bridges”) [11].  
The main risk factor for NSCLC is smoking. However, radiation therapy and 
environmental toxins such as second-hand smoke, asbestos or radon, and met-
als may also cause this type of cancer [7]. Patients with lung cancer are usually 
diagnosed at a late stage since symptoms do not manifest until they are locally 
advanced or there is metastatic disease. Cough, haemoptysis, chest pain, dysp-
noea or hoarseness may be indicative of lung cancer.  
EMA: licensed for 
squamous NSCLC  
in July 2015 
4,371 new lung cancer 
cases in Austria and 
52,717 in Germany  
each year 
most common type of 
lung cancer is non-small 
cell lung cancer 
main risk factor: 
smoking 
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For diagnosis, it is recommended to take a first-imaging chest x-ray followed 
by a CT scan, a clinical history, a physical exam and to conduct laboratory 
tests. To further characterise the tumour’s pathology, small biopsy samples 
should be taken and cytology should be performed; immune-histochemical 
staining (IHC) serves to differentiate the cancer histologically. Since the pres-
ence of specific genetic mutations – i.e. mutations in the epithelial growth 
factor receptor (EGFR) and rearrangements of the anaplastic lymphoma ki-
nase (ALK) genes – enables administration of targeted therapies, patients with 
non-squamous NSCLC should be tested for EGFR mutations and ALK rear-
rangements before the initiation of first-line treatment. Due to the low inci-
dence of these mutations in patients with squamous-cell NSCLC, testing of 
these mutations is not recommended in Europe. The only exception being 
people who never smoked or people who are former light smokers [7, 12].  
After this initial evaluation, staging of the cancer according to the Tumor 
Node Metastasis (TNM) system is done to determine the appropriate thera-
py as well as for deriving a prognosis. The TNM system groups lung cancer 
into 4 stages, based on the size of the tumour and presence or absence of nod-
al and distant metastases. Besides the extent of the disease, prognostic fac-
tors include European Cooperative Oncology Group (ECOG) Performance 
Status, gender and weight loss [12]. Even though survival rates have been in-
creasing constantly with the year of diagnosis, still only 18% of all patients 
with lung cancer are alive 5 years after diagnosis [8]. Patients at early stages 
survive for a median of 59 months, whereas patients with advanced stage IV 
disease have a life expectancy of about 4 months. In Austria, of newly diag-
nosed lung cancer patients, 34% of tumours were disseminated.  
 
 
 
5 Current treatment 
For the first-line therapy of patients with NSCLC without mutations and a 
good performance status (ECOG 0–2), a platinum-based doublet chemother-
apy is recommended [7]. Patients with a performance status (PS) of 0–2 who 
are progressing on first-line therapy should be offered second-line chemother-
apy. Single-agent therapy is preferred, since combination regimens have not 
shown superior results. For patients with squamous histology, docetaxel is 
indicated according to recent guidelines [7, 13]. For patients not eligible for 
chemotherapy, erlotinib is currently recommended for all NSCLC histologi-
cal subtypes.  
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6 Evidence 
A literature search was conducted on 19 June 2015 in four databases (Med-
line, Embase, CRD Database and The Cochrane Library). Search terms used 
were “Nivolumab”, “bms 936558”, “mdx 1106”, “ono 4538”, “Opdivo”, “PD-
1 inhibitor*”, “PD-L1 inhibitor*”, ” PD-1 receptor*”, “PD-L1 receptor*”, 
“Programmed Cell Death 1 Receptor”, “Carcinoma, Non-Small-Cell Lung”, 
“non-small cell lung”, “nonsmall cell lung”, “NSCLC*”. 424 references were 
identified.  
The manufacturer submitted 2 full-text publications, both already identified 
by the systematic search, and 3 presentations of which one provided addition-
al information to the phase III study and was therefore included [14]. 
 
 
6.1 Efficacy and safety – phase III studies 
Table 1: Summary of efficacy 
Study title  
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [15, 16]  
Study  
identifier 
CheckMate 017; ClinicalTrials.gov number NCT01642004; Protocol number CA209017;  
IND number 100052; EUDRACT number 2011-004792-36 
Design randomised, open-label, international phase III trial 
Duration  Enrolment: October 2012–December 2013 
Median follow-up: minimum follow-up app. 11 months 
Cut-off dates for interim analysis: database lock 15 December 2014 
On 10 January 2015, early termination of the study was recommended on 
the basis of a pre-specified interim analysis showing that overall survival 
among patients receiving nivolumab was superior to that among patients 
receiving docetaxel. 
Hypothesis Superiority 
Initially, confirmed objective response rate was also a primary end point, but on the basis of mature 
data regarding the objective response rate in an expanded cohort of patients with NSCLC who had 
been treated in the phase 1b study MDX-1106-03 (ClinicalTrials.gov number NCT00730639), the 
ongoing trial was amended before the planned interim analysis to make overall survival the sole 
primary end point. 
The boundary for declaring superiority for overall survival at the interim analysis was a P value of 
less than 0.03, which was based on an O’Brien-Fleming alpha-spending function. If the P value for 
overall survival indicated statistical significance, then the key secondary end points of response rate 
and progression-free survival were tested hierarchically at the 5% alpha level.  
Funding Bristol-Myers Squibb 
Treatment 
groups 
Overall study population: 272 
I(ntervention) 
(n=135) 
nivolumab intravenously (IV), at a dose of 3 mg per kilogram of body weight 
every 2 weeks until disease progression or discontinuation of treatment owing 
to toxic effects or for other reasons; dose reductions were not permitted; 
after initial disease progression treatment was permitted at the 
investigator’s discretion  
C(ontrol) 
(n=137) 
docetaxel intravenously, at a dose of 75 mg/m² of body-surface area every  
3 weeks until disease progression or discontinuation of treatment owing to 
toxic effects or for other reasons 
search in 4 databases 
 
424 references in total 
 
1 phase III and  
1 phase II study included  
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Endpoints and 
definitions 
Overall survival 
(primary outcome) 
OS time from randomisation to the date of death 
Objective response 
rate  
ORR number of subjects with a BOR (= best response designation, as 
determined by the investigators, recorded between the date of 
randomisation and the date of objectively documented progression per 
RECIST 1.1 or the date of subsequent anti-cancer therapy, whichever 
occurs first) of CR or PR divided by the number of randomised subjects 
Progression-free 
survival  
PFS time from randomisation to the date of the first documented event 
of tumour progression, death, or last tumour assessment that could 
be evaluated 
Patient-reported 
outcomes 
QoL disease-related symptoms and health status were assessed with the 
use of the Lung Cancer Symptom Scale and the European Quality of 
Life-5 Dimensions questionnaire. Outcome measures included the 
proportion of patients who had clinically meaningful improvement 
in the average Lung Cancer Symptom Scale score by week 12 
Duration of 
response 
DOR defined as the time between the date of first confirmed response to 
the date of the first documented tumour progression (per RECIST 1.1), 
or death due to any cause, whichever occurs first 
Results and analysis 
Analysis  
description 
OS and PFS were analysed via a two-sided log-rank test stratified by prior use of paclitaxel, and region. 
The HR and the corresponding confidence intervals (CI) have been estimated using a stratified 
Cox proportional hazards model. Survival curves for each randomised arm have been estimated 
using the Kaplan-Meier (KM) method.  
Analysis  
population 
Inclusion  stage IIIB or IV squamous-cell NSCLC who had disease recurrence after 
one prior platinum-containing regimen 
 ECOG PS score ≤1 
 patients with stable brain metastases were eligible 
 submission of a pre-treatment tumour-tissue specimen for  
biomarker analyses 
 prior maintenance therapy, including an epidermal growth factor 
 receptor tyrosine kinase inhibitor, was allowed 
Exclusion  autoimmune disease, symptomatic interstitial lung disease, systemic 
immunosuppression, prior therapy with T-cell co-stimulation or 
checkpoint-targeted agents, or prior docetaxel therapy 
 more than one prior systemic therapy for metastatic disease 
Characteristics  I C 
Median age (range), yrs 62 (39–85) 64 (42–84) 
Males/Females, % 82/18 71/29 
Disease stage IIIB/IV, % 21/78 18/82 
Smoking status: current smoker or 
former smoker/never smoked, % 
90/7 94/5 
Other previous systemic therapy, % 
Gemcitabine 
Paclitaxel 
Vinorelbine 
Etoposide 
Pemetrexed 
Bevacizumab  
Fluorouracil 
Cetuximab 
 
 
44 
34 
15 
13 
1 
1 
0 
 
 
52 
34 
8 
2 
1 
0 
1 
Time from completion of most recent 
prior regimen, % 
<3 months 
3–6 months 
>6 months 
 
 
47 
26 
26 
 
 
43 
29 
27 
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Descriptive 
statistics and 
estimated 
variability 
Treatment group I C 
Number of subjects N=135 N=137 
Median OS months, (95%CI) 9.2 (7.3–13.3) 6.0 (5.1–7.3) 
OS at 1 year %, (95%CI) 42 (34–50) 24 (17–31) 
ORR %, (95%CI) 20 (14–28) 9 (5–15) 
Best overall response 
Complete response  
Partial response  
Stable disease  
Progressive disease 
Could not be determined  
 
1 (1) 
26 (19) 
39 (29) 
56 (41) 
13 (10) 
 
0 
12 (9) 
47 (34) 
48 (35) 
30 (22) 
PFS months, (95%CI) 3.5 (2.1–4.9) 2.8 (2.1–3.5) 
Median DOR months, (range) NR (2.9–20.5*) 8.4 (1.4*–15.2*) 
QoL NA NA 
Effect estimate 
per comparison 
Comparison groups  I vs C 
OS HR 0.59 
95%CI 0.44–0.79 
P value <0.001 
ORR Odds ratio 2.6 
95%CI 1.3–5.5 
P value 0.008 
PFS HR 0.62 
95%CI 0.47–0.81 
P value <0.001 
Abbreviations: CI = confidence interval; CR = complete response; ECOG = Eastern Cooperative Oncology Group; HR = hazard 
ration; NA = not available; NR = not reached; n = number; PR = partial response; PS = performance status 
* This is a censored value. The value of 1.4 was censored owing to the start of subsequent therapy in one patient, and 
the other values were censored because the response was ongoing at the time of analysis.  
Table 2: Treatment-related adverse events of any grade reported in ≥ 20% of patients in either group  
and of grade 3 or 4 in ≥ 3% 
Grade (according  
to CTC version 4.0) Outcome, n (%) 
I  
(n=131) 
C  
(n=129) 
Any Grade Any event 76 (58) 111 (86) 
Fatigue 21 (16) 42 (33) 
Decreased appetite 14 (11) 25 (19) 
Nausea  12 (9) 30 (23) 
Diarrhoea  10 (8) 26 (20) 
Anaemia  2 (2) 28 (22) 
Neutropenia  1 (1) 42 (33) 
Alopecia 0 29 (22) 
Grade 3 or 4 Any event 9 (7) 71 (55) 
Fatigue 1 (1) 10 (8) 
Asthenia 0 5 (4) 
Anaemia 0 4 (3) 
Leukopenia 1 (1) 5 (4) 
Neutropenia 0 38 (30) 
Febrile neutropenia 0 13 (10) 
Grade 5 Any serious event 0 3 (2) 
Treatment-related deaths 0 3 (2) 
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The CheckMate 017 trial, an open-label phase III study, compared nivolumab 
with docetaxel in a total of 272 patients with squamous-cell NSCLC who had 
previously been treated with one platinum-containing regimen [15]. Patients 
had a median age of 63 years, the majority were men (76%) and 56% were 
younger than 65 years. Patients had advanced/metastatic disease and an 
ECOG of ≤ 1. 6% had never smoked, whereas 92% were either current or 
former smokers. Besides cisplatin or carboplatin other previous therapies in-
cluded gemcitabine (48%), paclitaxel (34%), and vinorelbine (16%) as well as 
other agents such as etoposide and monoclonal antibodies. After a median of 
8 doses nivolumab and 3 doses docetaxel, 36% in the nivolumab group and 
30% in the docetaxel group received further systemic therapy. 24% in the 
nivolumab group subsequently received docetaxel and 2% in the docetaxel 
group received further immunotherapy. 
In January 2015, the study was terminated early due to the results of an in-
terim analysis, showing that overall survival was superior for nivolumab. In 
this interim analysis, median OS, the primary outcome, was improved by 3.2 
months in patients treated with nivolumab, resulting in a hazard ratio of 0.59 
(p<0.001) compared to docetaxel. The OS rate at 1 year was 42% with nivo-
lumab compared to 24% with docetaxel. Consistent results were also shown 
in most subgroup analyses, according to previous chemotherapy, gender and 
smoking status [16]. Only in the small subgroups of patients aged ≥ 75 years 
(29 patients) and for the 31 individuals from the rest-of-the-world geograph-
ic region outcomes indicated improvements for docetaxel.  
An objective response, as assessed by investigators and RECIST criteria v 1.1, 
was achieved in statistically significantly more patients in the nivolumab group 
(20%) than in the docetaxel group (9%). Only 1% showed a complete response 
with nivolumab and none with chemotherapy. Partial responses were observed 
in 19% in the intervention group (I) and in 9% in the comparison (C) group. 
29% versus 34% had stable and 41% versus 35% had progressive disease re-
spectively. In the remaining cases, best overall response could not be deter-
mined with a substantial difference between the nivolumab group and the 
docetaxel group (10% vs 22%). Time to response was similar in both groups, 
however, at the interim analysis duration of response had not been reached 
with nivolumab therapy but was 8.4 months with docetaxel. Median progres-
sion-free survival (PFS) was extended by 0.7 months for patients treated with 
nivolumab.  
PD-L1 expression was evaluated retrospectively as a secondary endpoint in 
225 of the 272 patients using a validated automated IHC assay. Outcomes 
were analysed for different expression levels (1%, 5% and 10%). No differ-
ences were found between PD-L1-positive and -negative tumours. PD-L1 ex-
pression was therefore neither predictive nor prognostic for any outcome.  
In terms of treatment-related adverse events (AEs), more patients in the do-
cetaxel group experienced AEs of any grade (I 58% vs C 86%) and of grade 3 
or 4 (I 7% vs C 55%). No grade 5 AEs were observed with nivolumab but 2% 
with docetaxel, and treatment discontinuation due to treatment-related AEs 
was also less frequent in the nivolumab group (3%) than in the docetaxel 
group (10%). Serious AEs of at least grade 3 (I 2% vs C 21%) were pneumon-
itis in the nivolumab group and (febrile) neutropenia and dehydration in the 
docetaxel group. Higher rates of treatment-related serious AEs in the docet-
axel group were mainly caused by haematologic toxic events and infections. 
Treatment-related select AEs, potentially due to immunologic aetiology, of 
at least grade 3 comprised colitis, pneumonitis and tubulointerstitial nephri-
CheckMate 017 trial 
compared nivolumab 
with docetaxel in  
272 previously treated 
patients with  
squamous-cell NSCLC  
early termination 
 
median OS + 3.2 months 
for nivolumab group 
 
OS rate at  
1 year 42% vs 24% 
statistically significant 
improvements in 
response rate mainly 
due to partial response 
 
duration of response  
not yet reached in 
nivolumab group and 
8.4 months in the 
docetaxel group 
no difference in 
outcomes according to 
PD-L1 expression 
AEs 58% vs 86%, 
serious AEs 2% with 
nivolumab and 21% 
with docetaxel 
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tis (I 1% vs C 0% each) [14]. Immune-modulating medication, most often glu-
cocorticoids, was administered in 18%–100% of patients, depending on the 
grade of the observed AEs [16].  
 
 
6.2 Efficacy and safety – further studies 
The CheckMate 063 trial was a single-arm phase II trial assessing nivolumab 
in 117 squamous-cell NSCLC patients who had received two or more prior 
therapies [17, 18]. Patients had to have disease progression or recurrence af-
ter both a platinum doublet-based chemotherapy and at least one additional 
systemic therapy. Included patients were on average 65 years old, had an 
ECOG of ≤ 1 and had received 2 (35%), 3 (44%) or ≥ 4 (21%) previous ther-
apies. Since best response to the last therapy was progressive disease in 61% 
of cases, the majority of patients can be considered refractory.  
Objective response assessed by an independent radiology review committee 
was the primary outcome. 0% of patients achieved a complete response, 15% 
a partial response, 26% had stable disease and 44% progressive disease. Me-
dian PFS was 1.9 months, median OS 8.2 months, and the OS at 1 year was 
40.8%. PD-L1 expression was measured (cut-off 5%) in 88% of participants, 
of which 33% had PD-L1-positive tumours. More favourable objective re-
sponses and reductions in target tumour lesion burden were observed for pa-
tients with PD-L1-positive tumours.  
In terms of safety outcomes, treatment-related AEs of any grade were observed 
in 74% and of grade 3 or 4 in 17%. Most common AEs of any grade were fa-
tigue (33%), decreased appetite (19%) and nausea (15%) whereas fatigue (4%), 
pneumonitis (3%) and diarrhoea (3%) were the most frequent grade 3 or 4 AEs. 
Two deaths were considered to be treatment-related; one case of hypoxic pneu-
monia and one ischaemic stroke.  
After a median treatment duration of 2.3 months, nivolumab therapy was end-
ed in most instances due to disease progression. 24% of patients subsequently 
received further therapy.  
 
 
 
7 Estimated costs 
No costs for nivolumab are available yet either for Austria or for Germany. 
However, in Germany treatment costs comparable to those of ipilimumab or 
vermurafenib are expected, which would be about € 20,000 per case [19]. 
According to UK Medicines Information, Opdivo® was launched in Japan at 
an annual cost of $ 143,000 per patient and analysts expect an annual cost of 
at least $ 110,000 in the US [20]. 
 
 
phase II study in  
117 patients with  
≥ 2 prior therapies 
0% complete responses, 
15% partial responses 
 
better outcomes for  
PD-L1-positive tumours 
AEs in 74%,  
grade ≥ 3 in 17% 
no costs for Austria or 
Germany available 
 
estimates:  
€ 20,000/case 
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8 Ongoing research 
Two ongoing phase III studies were found on www.clinicaltrials.gov and on 
www.clinicaltrialsregister.eu assessing nivolumab therapy in NSCLC, in-
cluding both squamous as well as non-squamous cancers.  
 NCT02041533 (CheckMate 026): Evaluating nivolumab versus inves-
tigator’s choice chemotherapy as first-line therapy in subjects with 
strongly stage IV or recurrent PD-L1-positive NSCLC. Estimated study 
completion date: January 2018. 
 NCT02477826 (CheckMate 227): Comparing nivolumab, or nivolumab 
plus ipilimumab with platinum-doublet chemotherapy in subjects with 
chemotherapy-naïve stage IV or recurrent NSCLC. Estimated study 
completion date: December 2020.  
Nivolumab is also under investigation in phase III for non-squamous NSCLC 
(CheckMate 057, NCT01673867, estimated completion date May 2016), gli-
oblastoma, head and neck carcinoma, renal cell carcinoma and gastric cancer. 
Current phase II studies of the drug are on chronic lymphocytic leukaemia, 
multiple myeloma, cervical cancer and colon cancer.  
 
 
 
9 Commentary 
The EMA granted marketing authorisation of nivolumab for the treatment 
of locally advanced or metastatic squamous-cell NSCLC after prior chemo-
therapy in adults in July 2015 [6]. Similarly, the drug was licensed in March 
2015 by the FDA for the same indication but specifying previous therapy as 
platinum-based chemotherapy.  
Based on the findings of the CheckMate 017 trial it was decided to license 
nivolumab for squamous-cell NSCLC, making it the first immunotherapy 
medicine licensed in the European Union for this cancer and the first to 
demonstrate improvements in OS [21]. Median OS, the primary outcome of 
this phase III trial, was increased by 3.2 months in the nivolumab group in 
comparison to the docetaxel group, resulting in a reduction of risk of death by 
41%. With 38%, the risk of progression or death was also statistically lower, 
leading to a gain in median PFS by 0.7 months. Duration of response was 
not yet reached in the nivolumab group and was 8.4 months in the docetaxel 
group. Response rates also favoured the PD-L1 inhibitor (20% vs 9%), with 
the majority being partial responses (19% vs 9%). However, response rate 
could not be determined in a substantial number of patients particularly in 
the docetaxel group (I 10% vs C 22%). The extent to which this difference 
may impact on the rates observed is as yet unknown.  
In terms of safety outcomes, treatment-related AEs were less frequent in the 
nivolumab group than in the chemotherapy group. Any-grade AEs occurred 
in 58% in the nivolumab group in comparison to 86% in the docetaxel group, 
and grade 3 or 4 AEs in 7% and 55% respectively.  
3 phase III studies 
ongoing for NSCLC 
under investigation for 
further tumour types 
market authorisation  
in Europe in July 2015 
and in March 2015 in  
the U.S.  
first immunotherapy 
showing prolonged OS: 
+ 3.2 months 
 
risk of progression or 
death reduced by 38% 
 
response rates also 
improved with 
nivolumab, but data 
missing in 22% of 
patients in docetaxel 
group 
fewer any-grade and 
serious AEs with 
nivolumab 
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With the development of targeted therapies such as EGFR tyrosine-kinase 
inhibitors (TKI) (e.g. gefitinib, erlotinib), new treatment options have become 
available for lung cancer. However, the influence of molecular mutations on 
predicting response of squamous-cell NSCLC to targeted therapies has not 
been properly investigated yet, since EGFR mutations are present in less than 
5% and ALK mutations are even rarer in this type of lung cancer [22, 23]. Eu-
ropean Guidelines therefore do not recommend routine EGFR testing in con-
firmed squamous-cell carcinoma before initiation of therapy. Thus, first-line 
therapy with a platinum-containing regimen followed by docetaxel after dis-
ease progression is currently recommended for squamous-cell NSCLC [7, 23].  
Due to few treatment options with unsatisfactory results, several new thera-
peutic options are under investigation for squamous-cell NSCLC. Immuno-
therapy, including PD-L1 inhibitors, has therefore been discussed with great 
interest in the clinical community. The gains in median OS and a doubling of 
1-year survival rates achieved by nivolumab are considered as clinically rele-
vant. However, these results stem from an interim analysis and long-term fol-
low-up data will only become available later, but subsequent therapies may 
distort OS outcomes. In terms of PFS, improvements were small, but tumour 
response has been measured using the RECIST criteria. Since immunother-
apy may lead to an initial lymphocyte infiltration and, accordingly, to a pre-
liminary volume gain, tumours may be falsely labelled as progressive. Thus, 
immune-related response criteria have been suggested to avoid early termina-
tion of therapy and to capture late responders [24]. However, no consensus 
exists on the duration of therapy in the light of ongoing radiographic progres-
sion or for patients who are not progressing. Also, prolonged responses have 
been observed after only few treatment cycles [25].  
Selection strategies for the identification of patients with the highest poten-
tial to benefit from this costly therapy are also under investigation. One po-
tential biomarker for patient selection is PD-L1 [26]. Not only its prognostic 
but also its predictive value for response to immune-checkpoint inhibitors is 
under investigation [27] even though nivolumab was licensed regardless of 
PD-L1 positivity or negativity. However, the currently available data is in-
consistent [28]. In the CheckMate 017 trial, no association of PD-L1 negativ-
ity or positivity with clinical outcomes was observed. In contrast, other stud-
ies have shown a correlation between PD-L1 expression and tumour response 
[26, 27]. This difference may be caused by the lack of standardised assays for 
determining PD-L1 expression, methods of sample preservation and defini-
tion of a cut-off value for PD-L1 positivity (currently ranging from 1% of 10% 
of stained tumour cells) [27, 29]. Thus, studies are needed that compare out-
comes for patients assessed as PD-L1-negative compared to those assessed as 
PD-L1-positive based on a standardised definition using a validated assay 
[27, 28]. Furthermore, since PD-L1 expression is influenced by the tumour 
micro-environment, repeated assessment may be indicated but also difficult 
to implement in clinical practice [25, 26].  
Combinations of PD-L1 inhibitors with CTLA-4 inhibitiors such as ipili-
mumab, and combinations with other immune checkpoint modulators are 
under investigation, as they are expected to increase immune response by in-
creasing T-cell activity, and thus to improve the depth and duration of re-
sponses (CheckMate 227) [26, 30, 31]. Another advantage of combining agents 
with different modes of action may be overcoming resistance to targeted ther-
apies. On the other hand, as the spectrum of AEs is similar with respect to 
immune-related AEs such as colitis, hepatitis, pancreatitis or pneumonitis 
[32], there is concern that the frequency of these AEs could increase in com-
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bination therapies. This has been shown in other indications [33], therefore 
the safety of combined but also sequential administration of immune-thera-
pies in NSCLC should be assessed.  
Nivolumab is currently under investigation as second-line therapy for non-
squamous-cell NSCLC with first results showing also an increase in OS 
(CheckMate 057 trial [34]), in the first-line setting for NSCLC, and for other 
types of cancer. As a result, further extensions of indication can be expected. 
In terms of lung-cancer and with an expected extension to the more frequent 
non-squamous types, efficacy of nivolumab in tumours with EGFR and ALK 
mutations is of interest. Accordingly, the impact of previous targeted therapies 
or immunotherapy on the efficacy and safety of nivolumab needs to be inves-
tigated [31]. Moreover, with the prospect of nivolumab therapy being moved 
to earlier lines of therapy for potentially many more tumours, duration of 
therapy and re-treatment as well as long-term consequences of modifying the 
immune-system need to be evaluated [26]. 
Overall, improved outcomes in all assessed endpoints were demonstrated in 
the CheckMate 017 trial, with fewer AEs in comparison to standard second-
line chemotherapy. It is likely that the drug will become the new standard 
for the treatment of non-squamous NSCLC. Nonetheless, high costs are in-
curred, data for patient-reported outcomes have not been published yet and 
long-term adverse effects of immune therapies are unknown.  
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